Effects of Irbesartan on Metabolic Health
Author Information
Author(s): Klaus G Parhofer, Felix Münzel, Michael Krekler
Primary Institution: Medical Department II – Grosshadern, University Munich
Hypothesis
Does irbesartan therapy improve metabolic parameters in routine clinical practice?
Conclusion
Irbesartan therapy improves metabolic parameters in routine clinical settings.
Supporting Evidence
- Irbesartan therapy decreased systolic blood pressure by 14%.
- Body weight decreased by 2.3% after 6 months of therapy.
- Fasting glucose levels dropped by 9.5% during the study.
- LDL-cholesterol levels decreased by 11% after treatment.
- Triglycerides were reduced by 16% after 6 months.
Takeaway
Taking a medicine called irbesartan can help people with high blood pressure and diabetes feel better by making their blood sugar and cholesterol levels healthier.
Methodology
This was a 6-month, open-label, observational study involving 3259 patients with metabolic syndrome treated with irbesartan.
Potential Biases
Patients included in the study may not represent the general population, leading to potential selection bias.
Limitations
The observational design may introduce bias, and the study-in effect could influence results.
Participant Demographics
The cohort consisted of 64.1% men and 35.9% women, with an average age of 61.5 years.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website